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Abstract Barth syndrome (BTHS) is an X-linked disorder
characterised by cardiac and skeletal myopathy, growth delay,
neutropenia and 3-methylglutaconic aciduria (3-MGCA).
Patients have TAZ gene mutations which affect metabolism
of cardiolipin, resulting in low tetralinoleoyl cardiolipin
(CL4), an increase in its precursor, monolysocardiolipin
(MLCL), and an increased MLCL/CL4 ratio. During develop-
ment of a diagnostic service for BTHS, leukocyte CL4 was
measured in 156 controls and 34 patients with genetically
confirmed BTHS. A sub-group of seven subjects from three
unrelated families was identified with leukocyte CL4 concen-
trations within the control range. This had led to initial false
negative disease detection in two of these patients.
MLCL/CL4 in this subgroup was lower than in other BTHS
patients but higher than controls, with no overlap between the
groups. TAZ gene mutations in these families are all predicted
to be pathological. This report describes the clinical histories
of these seven individuals with an atypical phenotype: some
features were typica l of BTHS (f ive have had
cardiomyopathy, one family has a history of male infant
deaths, three have growth delay and five have 3-MGCA) but
none has persistent neutropenia, five have excellent exercise
tolerance and two adults are asymptomatic. This report also
emphasises the importance of measurement of MLCL/CL4
ratio rather than CL4 alone in the biochemical diagnosis of
the BTHS.
Introduction
Barth syndrome (BTHS, OMIM 3020660) is an X-linked
disorder of cardiomyopathy (CM) and skeletal myopathy
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accompanied by neutropenia which was first described by
Peter Barth and colleagues in 1983 (Barth et al 1983).
Growth retardation and 3-methylglutaconic aciduria (3-
MGCA) have also been described in BTHS (Kelley et al
1991), as well as a characteristic dysmorphology (Hastings
et al 2009) and male fetal death resulting in miscarriage and
stillbirth (Steward et al 2010).
BTHS is caused by mutations in the tafazzin (TAZ) gene
(Bione et al 1996) which encodes proteins that belong to a
family of acyltransferases known as tafazzins (Schlame et al
2002). These are involved in phospholipid biosynthesis, spe-
cifically in the incorporation of linoleic acid into
phosphatidylglycerol and cardiolipin (Vreken et al 2000).
Cardiolipin is a mitochondrial membrane phospholipid with a
tissue-specific structure (Schlame et al 2005). The most abun-
dant form in the mitochondria of human cardiac and skeletal
muscle is tetralinoleoyl cardiolipin (CL4). Deficiency of CL4
has been identified in a range of tissues in patients with BTHS
(Schlame et al 2002), as well as increased concentrations of its
precursor, monolysocardiolipin (MLCL) (Houtkooper et al
2009; Valianpour et al 2002a, b). These findings have also been
described in TAZ deficient yeast (Li et al 2007), Drosophila (Xu
et al 2006) and a knock-down mouse model of BTHS (Acehan
et al 2011), and are consistent with the hypothesis that the
disorder is caused by defective cardiolipin remodelling.
Over 120 mutations in the TAZ gene have been identified,
occurring in all 11 exons as well as at some splice sites
(Gonzalez 2013). Most are missense mutations, small dele-
tions or insertions, but some large exon deletions and one full
gene deletion have also been described. Most are predicted to
result in loss of function.
Patients with BTHS exhibit considerable phenotypic varia-
tion; the features of the disorder are variable both between
patients and within individual patients over time. For example,
someBTHS patients never developCM,many have CMwhich
ameliorates with age (Rigaud et al 2013; Roberts et al 2012;
Spencer et al 2006) and up to 10 % have not been identified as
being neutropenic at any stage (Clarke et al 2013). No
genotype/phenotype correlations have been identified.
We describe seven patients from three families with BTHS
confirmed by TAZmutation analysis who have some biochem-
ical and clinical features which differ from other BTHS cases
previously described, notably lack of severe deficiency of CL4
in leukocytes and absence of neutropenia; two are asymptom-
atic adults, one of whom has never had any features of BTHS.
Subjects and methods
Subjects
Subject 1 presented in the neonatal period with hypertrophic
CM and slightly increased urinary 3-MGCA. Three maternal
uncles had died in infancy, indicating possible X-linked dis-
ease in the family (Fig. 1a); he was therefore investigated for
BTHS. TAZ gene analysis identified a novel mutation in exon
2, c.170G>T (p.Arg57Leu), confirming the diagnosis.
Echocardiographic appearances improved steadily and at
12 years of age are normal apart from mild left ventricular
trabeculation; he is however still maintained on digoxin and
ACE inhibitors. He is very active, playing competitive sports
regularly including full soccer matches. His height and weight
are on the 25th and 75th centiles respectively. There was one
recorded episode of neutropenia (0.5×109) in the neonatal
period when he had CM, otherwise he has had no history of
neutropenia and has only contracted occasional routine child-
hood infections.
Subject 2, the older brother of subject 1, had an uneventful
neonatal course and achieved normal developmental mile-
stones. He underwent testing for BTHS following the diagno-
sis of the disorder in his brother. Platelet CL4 was measured
and reported as normal, and the diagnosis was therefore ex-
cluded. A diagnosis of BTHS was pursued subsequently with
TAZ gene mutation analysis because of the history of early
male death in this family; this identified the c.170G>T muta-
tion in exon 2 previously identified in his brother. His cardiac
function was therefore monitored and found to be normal
apart from mild left ventricular trabeculation. At the age of
14 years a cardiac arrhythmia was identified which has been
treated with a beta-blocker. Urine organic acid analysis has
recently shown 3-MCGA. He enjoys exercise, plays team
sports, cycles and is able to keep up with his peers. His height
is on the 50th centile and his weight on the 25th–50th centile.
He has never had an episode of recorded neutropenia.
Subject 3 is 44 years of age and is the maternal uncle of
patients 1 and 2. He presented in the neonatal period with
decompensated CM which responded well to treatment with
digoxin for one year. His cardiac function continues to be
monitored, but he is on no treatment and has had no further
cardiac disease. Following the diagnosis of BTHS in his
nephews, and in light of the history of early death of three
of his brothers, he underwent TAZ gene testing and the
familial mutation was identified. He has not been tested for
3-MGCA. He has normal exercise tolerance, has a physically
demanding job and is 1.85 m tall with a body-mass index
(BMI) of 24. He has no history of neutropenia or recurrent
infections.
Subject 4 is 47 years of age, the elder brother of subject 3.
His development was normal and he has no medical history of
note. Echocardiography performed at the time of the diagnosis
of BTHS in his nephew showed borderline septal and left
ventricular hypertrophy which did not require treatment. He
recently started treatment for essential hypertension. TAZ gene
mutation analysis was performed as part of the investigation
of his family for BTHS and the c.170G>Tmutation found. He
has not been investigated for 3-MGCA. He is very active,
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previously playing competitive football and has a physically
demanding job. He is 1.8 m tall and has a BMI of 32.
Neutropenia has not been detected.
Subject 5, from a second unrelated family (Fig. 1b), was
under investigation for global developmental delay and failure
to thrive when, at the age of 2 years, he presented with
congestive heart failure due to dilated cardiomyopathy
(DCM). A CM screen was normal apart from 3-MGCA on
urine organic acid analysis. The subsequent finding of DCM
in his younger brother (subject 6, described below) suggested
a genetic cause and he was investigated for BTHS. A novel
TAZ mutation, c.118A>G (p.Asn40Asp), was identified. His
cardiac function improved, allowing weaning of treatment
from the age of seven years; at 15 years of age his cardiac
function is normal on maintenance ACE inhibitors and di-
uretics. However he continues to have impaired motor skills,
skeletal myopathy, difficulty walking and problems with fa-
tigue, needing to take regular breaks during physical educa-
tion lessons at school. He also has significant learning diffi-
culties. His height is on the 0.4th centile and weight on the







Fig. 1 Pedigree and TAZ genotype of the families of subjects 1–7. Solid
squares indicate males with Barth syndrome. Carrier females are repre-
sented by circles containing a black spot. * indicates patient has not been
tested. Arrows indicate proband. (a) Subject 1=L; subject 2=K; subject
3=H; subject 4=F. (b) Subject 5=H; subject 6=I. (c) Subject 7=E
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Subject 6, younger brother of subject 5, presented at
13 months of age with bronchiolitis, requiring admission to
the Paediatric Intensive Care Unit (PICU). He was diagnosed
with DCM and 3-MGCAwas identified. Following the find-
ings in his brother, TAZ mutation analysis was performed and
the c.118A>G mutation identified. His CM resolved quickly
and by the age of 2 years all medication was stopped. He is
now 11 years old, is well, has no learning problems and has
normal cardiac function. He is active, joining in physical
education with his peers, but suffers fatigue after these les-
sons. His height and weight are on the 2nd–9th centiles. He
has had no episodes of neutropenia and no history of
infections.
Subject 7 from a third unrelated family (Fig. 1c), presented
to his local emergency department at 4 months of age with a
2-day history of poor feeding. Chest X-ray showed
cardiomegaly and echocardiogram showed a dilated left ven-
tricle (LV) with poor contractility. He became acidotic and
unwell and was transferred to PICU at a specialist paediatric
centre. Further echocardiogram suggested left ventricular
non-compaction. A CM screen was normal apart from a
slight increase in urine 3-MGCA. The screen included the
finding of normal bloodspot CL4. He was treated with di-
uretics, ACE inhibitors and a beta-blocker, resulting in im-
provement of LV function over the following year and an
increase of fractional shortening from 5 to 35 %. His presen-
tation was typical of other patients with BTHS seen by the
clinical team so further investigations were pursued.
Leukocyte MLCL/CL4 was measured and found to be above
the reference range, prompting TAZ mutation analysis which
identified a previously reported pathogenic mutation in exon
7, c.553A>G (p.Met185Val). His LV function has improved
from his initial presentation and is stable on ACE inhibitors,
digoxin and a beta-blocker. At 2 years of age he is well and
active; his motor skills are developing well. His height and
weight are on the 2nd–9th centile. He has had no recorded
neutropenia.
Cardiolipin analysis
Subjects 1, 2, 5 and 6 had blood samples taken on a routine
visit to the NHS BTHS service (NBSS) clinic at Bristol Royal
Hospital for Children (BRHC). An additional sample was
taken during routine venepuncture for leukocyte MLCL/CL4
analysis as part of development of a diagnostic test for BTHS.
MLCL/CL4 analysis in leukocytes was performed in subjects
3 and 4 following the findings in their nephews. Written
informed consent was obtained from the parents and, where
appropriate, the subjects for sample analysis to be performed.
Approval for this investigation was obtained from the local
NHS research ethics committee. Subject 7 had MLCL/CL4
measured due to a strong clinical suspicion that he had BTHS.
All except subjects 3 and 4 have had cardiolipin analysis
repeated on a later sample using the same method to confirm
the findings.
Leukocytes were extracted from K-EDTA blood, phospho-
lipids extracted, CL4 and MLCL(18:1)2(16:0) measured by
LC-MS/MS (Bowron et al 2013) and the MLCL/CL4 ratio
calculated. Results were compared with those obtained from
156 paediatric controls and 27 other patients with BTHS
confirmed by TAZ mutation analysis referred to the NBSS.
Mutation analysis
All seven patients had TAZ mutation analysis performed as
part of their investigations for BTHS or for family studies.
Consent for genetic testing was obtained at the time of sample
collection.
Genomic DNAwas received from an external laboratory or
isolated from peripheral blood leukocytes using a Gentra
Puregene cell kit (QIAGEN Ltd). Coding regions of the TAZ
gene (11 exons including intron/exon boundaries extending to
the branch sites) were amplified in ten fragments using a
MegaMix (MicroZone) and GC-RICH (Roche) PCR system.
Primers were designed to GenBank Reference Sequence
NM_000116.3 using Primer3 software (Koressaar and
Remm 2007; Untergasser et al 2012). M13 tagged bi-
directional sequencing was undertaken using a BigDye
Terminator v3.1 Cycle Sequencing Kit and 3730 DNA
Genetic Analyzer (Applied Biosystems) with Mutation
Surveyor DNA Variant Analysis Software v3.97
(Softgenetics). Alamut software v2.3.1 (Interactive
Biosoftware, Rouen, France) was used to predict the effect
of genetic variation. The software integrates PolyPhen-2,
Align GVGD and SIFT and five splice site prediction pro-
grams: SpliceSiteFinder, MaxEntScan, Human Splice Finder,
NNSPLICE and GeneSplicer.
Full blood counts
Neutrophil counts were recorded on subjects 1–7 during rou-
tine clinic appointments; 75 neutrophil counts were obtained.
These were compared with neutrophil counts measured on
other BTHS patients attending the NBSS; results were exclud-
ed from samples taken after patients had begun treatment with
granulocyte colony stimulating factor (G-CSF). Data was
obtained from their referring hospitals and from their outpa-
tient visits to BRHC. 652 neutrophil count results were ob-
tained from 15 patients.
Statistics
Data was analysed using GraphPad Prism (San Diego,
California, USA). Results from different groups of patients
were compared using a Mann–Whitney test with significance
set at p<0.05.
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Results
Leukocyte CL4 results from subjects 1–7 (median 127
pmol/mg protein [range 107–227]) were significantly higher
than those found in other BTHS patients (9.1 pmol/mg protein
[2.0–35], p<0.0001) and lower than control values (388
pmol/mg protein [60–872], p<0.0001). The CL4 results in
subjects 1–7 overlapped with the lower quartile of the control
values. The MLCL/CL4 ratios in subjects 1–7 (0.14 [0.08–
0.30]) were lower than in other BTHS patients (9.4 [1.8–33],
p<0.0001), but higher than controls (0.6×10−4 [1.0×10−4−
0.02] p<0.0001). There was no overlap between the three
groups (Fig. 2).
Only one low neutrophil count has been recorded in sub-
jects 1–7 (0.5×109 in subject 1 during the neonatal period
when he had CM). The values recorded in this cohort were
significantly higher than neutrophil counts obtained from
other BTHS patients (p<0.0001) (Fig. 3).
Discussion
We have described seven subjects from three families with
BTHS confirmed by the finding of a mutation in the TAZ gene.
They do not have profound CL4 deficiency typical of BTHS,
although increased MLCL confirms that there is an abnormal-
ity in cardiolipin remodelling. We believe this to be the first
description of BTHS without severe CL4 deficiency. In two
subjects, platelet or bloodspot CL4 had been measured previ-
ously and found to be normal, resulting in the diagnosis of
BTHS being excluded initially. This was subsequently revised
due to family history or clinical features and the finding of a
MLCL/CL4 ratio significantly above the reference range; this
highlights the importance of measurement of this ratio, rather
than isolated assay of CL4, when performing biochemical
investigation of BTHS.
The mutation c.170G>T in exon 2 (p.Arg57Leu) was
found in subjects 1–4. Arginine at position 57 is highly
conserved and is predicted to have a strongly adverse effect
on protein function (Alamut 2013) (Table 1). Ayeast model of
BTHS has been used to investigate biochemical function of 21
tafazzin mutations. The corresponding yeast mutation,
y.Lys65Leu, demonstrated wild-type acyltransferase activity
at 30 °C, but demonstrated some thermolability with reduced
acyltransferase activity and increased MLCL/CL at 37 °C
(Whited et al 2012). The clinical course of surviving members
of this family with BTHS has been relatively mild. However it
is important to note the family history. Both subjects 1 and 3
had a severe cardiac presentation in the neonatal period and
three maternal uncles of the two boys died in infancy: one at
four months (reportedly due to myocarditis), the second at
birth following a breech delivery (the exact cause of death is
unknown) and the third of E.Coli infection on day one of life
proceeding to cardiac arrest and death from pneumonia. These

















Fig. 3 Box-and-whisker plot of neutrophil counts in patients 1–7 com-
pared with other patients with BTHS. Results from subjects 1–7 are
significantly higher than other BTHS patients p<0.0001
































Fig. 2 Box-and-whisker plot of results of (a) CL4 and (b) MLCL/CL4
analysis in patients 1–7 compared with controls and other patients with
BTHS. The horizontal bar represents the median, the box the interquartile
range and the vertical bars the range. There is a significant difference
between all three groups on each graph p<0.0001






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































284 J Inherit Metab Dis (2015) 38:279–286
deaths preceded discovery of the TAZ gene and development
of cardiolipin analysis so BTHS cannot be confirmed, al-
though these histories are strongly suggestive. If they did have
BTHS, this demonstrates that this mutation, whilst conferring
relativelymild disease in the four subjects described here, may
have a severe disease course, possibly under different envi-
ronmental challenges or in combination with other gene var-
iants. These findings emphasise the wide phenotypic variation
in BTHS, even within the same family.
The TAZ variant found in subjects 5 and 6, c.118A>G
(p.Asn40Asp), is at a highly conserved amino acid position
and is predicted to have an adverse effect on the protein using
SIFT in silico analysis; although another tool, PolyPhen-2, is
inconclusive with its pathogenicity prediction (Alamut 2013)
(Table 1). The corresponding yeast mutation, y.Asn48Asp, has
been reported to have identical biochemical activity to wild type
yeast at both 30 °C and 37 °C, indicating that it has no effect on
yeast tafazzin function (Whited et al 2012). However, as there is
no population frequency data available for this variant it is
unlikely to be a benign polymorphism. These two boys both
had severe cardiac disease in early childhood accompanied by 3-
MGCA, indicating that this TAZ variant has pathological effects.
The mutation in subject 7, an exon 7 variant c.553A>G,
predicts the substitution p.Met185Val. Bioinformatics tools indi-
cate that this has an adverse effect on protein function, generating
a new splice donor signal within exon 7 (Alamut 2013) (Fig. 4,
Table 1). Functional RNA analysis proved that this mutation
causes retention of intron 6 and partial deletion of exon 7,
confirming pathogenicity (r.[541+1_542-1 ins; r.553_583del];
p.Lys182Glnfs*4) (Fan et al 2013). The mutation has not been
modelled in yeast. Fan et al recently described a patient with this
mutation; he had DCM requiring cardiac transplantation, neutro-
penia (0.5×109/L) treated with G-CSF and an increased lym-
phoblast cell line MLCL/CL ratio consistent with BTHS.
Urine organic acid analysis was performed in five of this
group of subjects and 3-MGCA found in each on at least two
occasions. It is known that 3-MGCA is an inconsistent feature of
BTHS (Rigaud et al 2013; Schmidt et al 2004; Wortmann et al
2012) although the mechanism for this organic aciduria is not
known. The patient described by Fan et al had no 3-MGCA on
multiple urine organic acids analyses, whereas subject 7 in our
studywith the samemutation had 3-MGCA identified on at least
three occasions on samples measured in two different laborato-
ries. The variation in 3-MGCA between two unrelated patients
with the same TAZ gene mutation indicates that 3-MGCA
excretion has other influences which are not understood.
BTHS patients attending the NBSS exhibit characteristic
slow linear growth with a trend of increasing adiposity
throughout adolescence (Clarke et al 2013). Subjects 5–7 have
height and weight consistent with this. Whilst subjects 1 and 2
Fig. 4 In silico analysis of the
TAZ c.553A>G variant found in
patient 7 using various splicing
prediction programs (Alamut
v2.3.1). Top section pale blue
shaded area is wild-type
sequence. Bottom section is
mutated sequence. Dark blue bars
represent predicted donor splice
sites. Green bars represent
predicted acceptor splice sites.
The diagram shows the creation
of a new strong donor splice site
at the variant position
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are taller than many BTHS patients, their heights fall within
the range seen in our clinic.
The clinical phenotype of this group is therefore relatively
mild and atypical for BTHS. Only one of this group suffers
from skeletal myopathy. Exercise tolerance is excellent in five
and hard to assess due to young age and concomitant CM in a
sixth. Subjects 1–4 have been able to take part in full compet-
itive sport. Two of the subjects have no history of CM. Finally,
none of the BTHS subjects described in this report has chronic
neutropenia or recurrent infection as a feature of their disease.
In conclusion, this report demonstrates that some TAZ
mutations do not result in profound CL4 deficiency and high-
lights the importance of measurement of MLCL/CL4 rather
than CL4 alone in the biochemical diagnosis of BTHS. In this
group of subjects without severe CL4 deficiency, neutrophil
counts are significantly higher than in other BTHS subjects
and the disease course so far is relatively mild, suggesting a
possible ameliorated form of BTHS and a correlation between
biochemistry and phenotype. Further investigations into the
function of these mutations and the resulting biochemical and
clinical phenotype may help to elucidate the role of tafazzin
and the pathogenesis of this complex multi-system disorder.
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